Strata Critical Medical earnings date
Want to see SRTA full AI Analyst Report?
Strata Critical Medical (SRTA) Q3 2026 Earnings Report
SRTA Q3 2026 EPS Results
- Actual EPS
- -$0.09
- Consensus EPS
- -$0.01
- Beat/Miss
- Missed by -$0.08
- One Year Ago EPS
- -$0.04
SRTA Q3 2026 Revenue Results
- Actual Revenue
- $74.08M
- Expected Revenue
- $72.67M
- Beat/Miss
- Beat by +$1.41M
- YoY Revenue Growth
- +50.27%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/03/2026
- Time
- Before Open
- Conference Call
- Tuesday, November 3, 2026
Strata Critical Medical's next earnings date is estimated for March 16, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive overall. Highlights included substantial revenue, EBITDA, margin and free cash flow growth; continued clinical market-share gains; early achievement of the logistics margin target; strong liquidity; acquisition capacity; and a new share repurchase authorization. The company did face seasonal transplant declines, shorter logistics distances, lower logistics revenue and year-over-year logistics gross margin, a sequential decline in clinical gross margin, elevated stock-based compensation and a GAAP loss caused by noncash items. However, management reiterated 2026 guidance and its medium-term growth targets, and the positive operating and strategic developments significantly outweighed the stated challenges.
Strata reiterated 2026 guidance for revenue of $285 million to $295 million, adjusted EBITDA of $33 million to $35 million and free cash flow before aircraft and engine acquisitions of $15 million to $22 million; at the midpoint, this implies a low single-digit sequential increase in revenue in the fourth quarter, with Q4 growth driven primarily by clinical, logistics expected to be about flat quarter-over-quarter and gross margin expected to remain about flat sequentially. The company anticipates an increase in clinical gross margins moving into 2027 and remains confident in its medium-term financial targets for high teens organic adjusted EBITDA growth and 30% plus adjusted EBITDA growth, including acquisitions; stock-based compensation expense is expected to decline sequentially approximately 20% to 30% moving into Q4, with the lower run rate expected to persist since 2027, alongside a continued reduction in SG&A as a percentage of revenue.
- Strong Q3 Revenue and Gross Profit GrowthTotal revenue increased 50.3% year-over-year to $74.1 million from $49.3 million, driven by clinical acquisitions and growth, partially offset by logistics. Total gross profit increased 57.9% to $16.8 million from $10.7 million.
- Clinical Segment Continued Taking ShareClinical revenue increased 20.3% sequentially in Q3 2026, driven primarily by the full-quarter impact of recent acquisitions and modest organic sequential growth. Clinical grew organically in a seasonally weak quarter when industry transplant volume declined approximately 7% sequentially, and like-for-like clinical year-over-year growth was 30% plus, with faster growth weighted toward transplant clinical.
- Improved Consolidated Gross MarginTotal gross margin increased 110 basis points year-over-year to 22.7% from 21.6%, driven primarily by the positive mix impact of the larger clinical segment, which also experienced margin expansion versus the prior-year period.
- Logistics Gross Margin Reached 2027 Target EarlyLogistics gross margin rebounded 240 basis points sequentially to 20.8% in Q3 from 18.4% in Q2 2026, well ahead of the company's goal to reach 20% in 2027. Improvements occurred across air, ground and TOPS.
- Adjusted EBITDA and Margin ExpansionAdjusted EBITDA increased to $9.6 million from $4.2 million in Q3 2025 and $7.9 million in Q2 2026. Adjusted EBITDA margin rose to 13% from 8.5% year-over-year and 10.9% sequentially.
- Record Free Cash Flow and Strong Cash PositionFree cash flow reached a record $8.6 million in Q3, while cash flow from operating activities was $9.5 million. Strata ended the quarter with $41.6 million in cash and short-term investments, after receiving $15.3 million of net proceeds from the first passenger-business earnout.
- Reduced Adjusted SG&A BaseAdjusted SG&A decreased $0.2 million sequentially and remained about flat over the last four quarters despite significant organic growth and the completion of three bolt-on acquisitions. The company also expects a continued reduction in SG&A as a percentage of revenue.
- 2026 Guidance ReiteratedStrata reiterated 2026 revenue guidance of $285 million to $295 million, adjusted EBITDA guidance of $33 million to $35 million, and free cash flow before aircraft and engine acquisitions of $15 million to $22 million.
- Positive Medium-Term Growth OutlookManagement remains confident in its medium-term targets of high teens organic adjusted EBITDA growth and 30% plus total adjusted EBITDA growth, including acquisitions. For 2027, growth is expected to be led by Clinical, with the resulting mix shift expected to drive continued improvement in free cash flow conversion relative to 2026.
- M&A Execution and Capacity to Accelerate AcquisitionsStrata is ahead of plan for 2026, having closed acquisitions representing over $6 million of expected annualized adjusted EBITDA at targeted mid-single-digit valuation multiples. Management said the company can now accelerate beyond its target acquisition pace, with a strong pipeline focused on opportunities that strengthen its strategic position and enhance margin and free cash flow conversion.
- Share Repurchase Authorization AnnouncedThe company announced a $20 million share repurchase authorization, citing its improved cash position, expected earnout receipts and what it views as an attractive valuation for its stock. Management said M&A remains the priority while allowing for opportunistic shareholder returns.
- Integrated Transplant Offering Expanded Customer ValueStrata's integrated platform combines organ recovery, perfusion, logistics and placement. Management said customers are saving money and completing more transplants, while integrated cases can represent as much as 3x the opportunity of transport-only cases and are weighted more heavily toward clinical revenue.
- Operational Efficiency ImprovementsStrata reported becoming more efficient by repositioning empty airplanes less, using two airplanes less and leveraging local surgeons and aircraft to reduce dry-run costs. Staff transportation is handled by ground or commercial air roughly two-thirds of the time, and the company said its owned and non-owned aircraft network provides flexibility to scale capacity.
- Expanded Preservation Device PartnershipsStrata currently stocks devices from OrganOx, Bridge to Life, Paragonix and Traferox at clinical hubs across the country, enabling transplant-center customers to use preservation and perfusion technologies according to their preferences.
- New Cardiothoracic Locum Tenens BusinessIn October, Strata launched its cardiothoracic surgical locum tenens business with its first customer, loaning surgeons and clinicians to hospitals for non-transplant use cases. Management described this as a large new addressable market that can increase surgeon utilization and support staff retention.
- Long-Term Transplant Market TailwindsDonation after circulatory death donors now represent over half of all transplants. Management expects broader adoption of NRP and continuous distribution, including potential future changes for heart and liver allocation, to support increased transplant volumes and longer distances over time. The company estimates DCD donors undergoing NRP could reach 80% by 2028 versus 60% currently.
- Limited Exposure to Tier 3 OPOsManagement said Strata has no large OPO customer representing 10% or greater of revenue and estimated minimal exposure to Tier 3 OPOs at approximately 3% based on the available prior-year data.
- No Near-Term Need for Additional Owned AircraftManagement stated that Strata does not require additional owned planes to operate efficiently or continue scaling its model. Any aircraft purchases in the near term are expected to be largely funded by sales of other aircraft or the release of deposits with third-party operators.
SRTA Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 16, 2027 | 2026 (Q4) | 0.01- | -0.06 | ― | ― |
| Nov 03, 2026 | 2026 (Q3) | -0.01-0.09 | -0.04 | -143.24% (-0.05) | |
| Aug 04, 2026 | 2026 (Q2) | -0.02-0.12 | -0.05 | -140.00% (-0.07) | |
| May 06, 2026 | 2026 (Q1) | -0.040.03 | -0.04 | 175.00% (+0.07) | |
| Mar 03, 2026 | 2025 (Q4) | 0.01-0.06 | -0.13 | 51.18% (+0.07) | |
| Nov 10, 2025 | 2025 (Q3) | 0.04-0.04 | -0.03 | -23.33% (-0.01) | |
| Aug 05, 2025 | 2025 (Q2) | -0.04-0.05 | -0.15 | 66.67% (+0.10) | |
| May 12, 2025 | 2025 (Q1) | -0.12-0.04 | -0.06 | 33.33% (+0.02) | |
| Mar 13, 2025 | 2024 (Q4) | -0.12-0.13 | -0.45 | 71.78% (+0.32) | |
| Nov 12, 2024 | 2024 (Q3) | -0.02-0.03 | 0 | ― |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


